Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ALX ONCOLOGY HOLDINGS INC (ALXO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
10/06/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"ALX ONCOLOGY HOLDINGS INC. FORM OF WARRANT TO PURCHASE COMMON STOCK",
"Follow-On Public Offering of ALX Oncology Holdings Inc.",
"ALX Oncology Announces Pricing of Public Offering"
10/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/04/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
10/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer — Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors — Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment — Company to host conference call and webcast today at 8:00 AM EDT"
08/25/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors SOUTH SAN FRANCISCO, Calif., August 10, 2023 --"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., May 11, 2023 --"
04/24/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones SOUTH SAN FRANCISCO, Calif., March 9, 2023 --"
02/14/2023 SC 13G ORBIMED ADVISORS LLC reports a 5.6% stake in ALX Oncology Holdings Inc.
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in ALX ONCOLOGY HOLDINGS INC
11/29/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
10/31/2022 8-K Quarterly results
08/10/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/10/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
06/01/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/27/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/26/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/13/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/09/2022 8-K Quarterly results
Docs: "Investor Contact:"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy